Therefore, it is tempting to hypothesize that the antiproliferative effect of these TZD compounds, including rosiglitazone, on MCF-7 breast cancer cells and PC3 prostate cancer cells could be mediated, at least in part, by the reduction in BCL-xL expression. Here, BCL2L1 is linked to breast carcinoma.